- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
MassBio Releases Digital Health Study for Massachusetts
The Massachusetts Biotechnology Council (MassBio) announced the release of its recent digital health report, Making Massachusetts a Leading Global Destination for Digital Health. The report, which was done by Deloitte, looks at the current state of the digital health industry in Massachusetts, challenges facing its growth, and opportunities the state has to lead.
The study also identified at least three key opportunities where Massachusetts stakeholders could invest time and resources to drive growth and differentiation of its digital health ecosystem These include, but are not limited to: fostering better access to data and patients; developing a workforce that is able to tackle complex healthcare challenges through digital technology; and better coordinating the digital health entrepreneur and investor ecosystems. In addition to advocating for what the state can do, MassBio plans to launch new initiatives to support digital health entrepreneurs.
To read or download the full report, visit here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
